Disitamab Vedotin

维迪西妥单抗

Report date: 2026/05/02 20:00:18

Base Information

Drug NameDisitamab Vedotin
Drug Alias Name重组人源化抗HER2单抗-MMAE偶联剂（荣昌生物）Trastuzumab-MMAE ADC (Remegen)纬迪西妥单抗Trastuzumab-MMAE antibody drug conjugate (Remegen)Vidicuzumab +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized +[4] 
Mechanisms of ActionTubulin polymerisation inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsTubulinReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[24] 
Global Approved IndicationsStomach Neoplasms
Approved Indications in ChinaStomach Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2021/06/08
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesRemeGen Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSeagen IncThe First Affiliated Hospital With Nanjing Medical UniversityPfizer Inc +[7] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[22] 
Inactive IndicationsBreast DiseasesNeoplasms

Other Information

ATC CodeL01X
Related LinksWikipediaDrugBankKEGG